Medication prescriptions related to suicidal ideations treatment in patients with overweight or obesity within 6-month follow-up time window (comparison between propensity-score matched groups)

Population	Semaglutide group	Non-GLP1R agonist anti-obesity medications group	p	HR (95% CI)
Overall (n = 865/group)	68.9% (596)	97.0% (839)	H	0.27 (0.24–0.31)
Women (n = 618/group)	68.9% (426)	95.1% (588)	Ħ	0.32 (0.28–0.37)
Men (n = 234/group)	70.9% (164)	97.0% (227)	 ■	0.24 (0.19–0.30)
age <= 45 years (n = 446/group)	66.1% (295)	94.8% (423)		0.30 (0.26–0.35)
age > 45 years (n = 409/group)	71.1% (291)	97.3% (398)		0.27 (0.23–0.33)
			0.10 0.20 0.40 0.80 2.0 4.0 8.0 Hazard Ratio (HR)	